NCT06441045View on ClinicalTrials.gov

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

April 1, 2028

Study Completion Date

October 1, 2028

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

Double Dose of Third-generation EGFR-TKI

Double Dose of Third-generation EGFR-TKI

DRUG

Intrathecal Pemetrexed

Intrathecal Pemetrexed

Trial Locations (1)

Unknown

Gen Lin, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV